Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GCK | P35557 | 3/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15880257 | 0.80 | L3MBTL1 (0.45) | L3MBTL1GCKACLYTDP1MAPT | |
| SCHEMBL15880931 | 0.80 | TDP1 (0.58) | L3MBTL1KDM4ETDP1MAPTALDH1A1 | |
| SCHEMBL15912474 | 0.75 | TDP1 (0.48) | L3MBTL1TDP1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL8343718 | 0.75 | MAPT (0.52) | MAPTPOLB | |
| SCHEMBL31214279 | 0.71 | NPSR1 (0.48) | L3MBTL1KDM4ETDP1NPSR1MAPT | |
| SCHEMBL958881 | 0.71 | NPSR1 (0.48) | L3MBTL1KDM4ETDP1NPSR1MAPT | |
| SCHEMBL31231846 | 0.71 | NPSR1 (0.41) | NOTUMNPSR1 | |
| SCHEMBL15543442 | 0.71 | NPSR1 (0.41) | NOTUMNPSR1 | |
| SCHEMBL4918494 | 0.70 | P2RX7 (0.35) | L3MBTL1NOTUMKDM4EACLYTDP1 | |
| SCHEMBL15880429 | 0.69 | ALDH1A1 (0.49) | L3MBTL1TDP1MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | L3MBTL1 2087/4885NOTUM 1014/4885KDM4E 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.